

Financial Tear Sheet

Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome and completed a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Stock Performance

OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$8.33
Change (%)	▲ 0.05 (0.60%)
Volume	40,117
52 Week High	\$15.05
52 Week Low	\$5.28
Market Cap	\$203,882,307
Rolling EPS	-1.54
PE Ratio	0
Shares Outstanding	24,623,467

Data as of May 22, 2018 4:00 p.m. ET



Recent Headlines

May 9, 2018

Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)

May 8, 2018

Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

May 2, 2018

Ovid Therapeutics to Present at Deutsche Bank's 43rd Annual Health Care Conference on May 9, 2018

SEC Filings

Filing Date

Form

May 8, 2018

8-K

May 8, 2018

10-Q

April 24, 2018

DEFA14A

April 24, 2018

DEF 14A

Upcoming Events

There are currently no events scheduled.

Corporate Governance

Jeremy Levin, D.Phil.,
MB BChir

Chairman of the
Board of
Directors

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.